If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
6.85    0.35 (5.38%)
Bid:
6.70
Ask:
7.00
Spread: 0.30 (4.478%)
Market Cap: £3.00m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Directorate Change

14 Feb 2018 07:00

RNS Number : 8078E
Feedback PLC
14 February 2018
 

This announcement contains inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 (MAR).

14 February 2018

Feedback plc

 

("Feedback" or the "Company")

 

Directorate change

Appointment of new Chief Executive Officer to drive growth strategy

Cambridge, UK - 14 February 2018: Feedback plc ("Feedback" or the "Company") (AIM: FDBK), the specialist medical imaging technology company, announces that it has appointed David Crabb as Chief Executive Officer and a director of Feedback with immediate effect. This appointment will underpin the execution of the Company's growth strategy following the first CE marked release of TexRAD®; the Company's patented quantitative image texture analysis technology for diagnostic radiological scans.

Mr Crabb brings 20 years of experience as an effective business leader to Feedback. Most recently he was Chief Executive Officer of Cambridge Online Systems, a major software company providing services to UK and international customers, which was acquired by the global IT group Columbus in December 2016. Under Mr Crabb's management in 2011, Cambridge Online Systems delivered strong growth from a loss-making organisation to one with top-quartile financial results and was voted as one of the "Sunday Times Top 100 Companies to work for" in two consecutive years. Previously, Mr Crabb held director-level roles in medium-sized technology and outsourced solutions companies with revenues from £50 million to over £1 billion, responsible for business optimisation, sales and marketing and workforce leadership.

Dr Alastair Riddell, Chairman of Feedback plc, said: "Since the acquisition of Cambridge Computed Imaging Ltd and TexRAD Limited in 2014, Feedback plc has developed a strong reputation in the field of medical imaging and is privileged to be working with over 40 of the world's leading research institutions. We recognise that a small, multi-disciplinary team has its limitations, which resulted in some operational delays over the past 12 months, so I am delighted that Feedback has attracted a highly experienced executive to complement the strong technical and regulatory expertise within the Company. Under David's leadership, we are well-positioned to leverage our pioneering technology to create evidence-based imaging software, arming clinicians with innovative tools to improve patient outcomes."

David Crabb, Chief Executive Officer of Feedback plc, commented: "I am impressed with the platform technologies and domain expertise at Feedback. The medical imaging and diagnostics market is a dynamic, fast-paced environment where disruptive technologies are very much needed. The opportunity is not without its challenges, as with all pioneering development, but as a small, ambitious company which has experienced both acquisition and organic growth, there is significant opportunity to optimise and expand Feedback's operations. Our long-term vision is to lead global innovation in quantitative medical imaging analysis - I believe we have strong foundations to position ourselves at the forefront of this important field and I am looking forward to refining our strategy over the coming months."

Regulatory Disclosures

In accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies, David James Crabb, aged 50 is, or has been within the last five years, a director or partner in the following companies and partnerships: 

Current directorships and partnerships

Past directorships and partnerships held within the last five years

David Crabb Consulting Limited

Cambridge Online Systems Limited

 

There is no other information required to be disclosed under the AIM Rules for Companies.

Notes to editors

About Feedback plc

Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.

 

For further information, please contact:

 Feedback plc

David Crabb, Chief Executive Officer

Lara Mott, Investor Relations

 

Tel: 01954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser and Joint Broker)

David Worlidge / Asha Chotai

Tel: 020 3328 5656

Northland Capital Partners Ltd (Joint Broker)

David Hignell / John Howes

Tel: 020 3861 6625

Peterhouse Corporate Finance Ltd (Joint Broker)

Lucy Williams / Duncan Vasey

Tel: 020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATJMJTMBABTBP
Date   Source Headline
10th Sep 20187:00 amRNSTexRAD® ordered by Samsung Medical Centre in Seoul
17th Aug 20182:02 pmRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSFirst GE Healthcare order for TexRAD®
1st Aug 20181:19 pmRNSDirector/PDMR Shareholding
20th Jul 20187:00 amRNSDirectorate Change
6th Jul 20187:00 amRNSJoint broker update
29th Jun 20183:20 pmRNSDirector/PDMR Shareholding
27th Jun 20187:00 amRNSGrant of Options and Director/PDMR Dealing
22nd Jun 20182:10 pmRNSResult of General Meeting
8th Jun 201810:36 amRNSHolding(s) in Company
7th Jun 20187:05 amRNSNotice of General Meeting
7th Jun 20187:00 amRNSRevised strategy to build a global company
1st Jun 20187:00 amRNSAppointment of new Medical Director
10th May 20189:27 amRNSHolding(s) in Company
4th May 20186:09 pmRNSHolding(s) in Company
1st May 20187:00 amRNSDirector/PDMR Shareholding
30th Apr 20185:00 pmRNSTotal Voting Rights
27th Apr 20187:00 amRNSTwo-year contract with Royal Papworth Hospital
25th Apr 20182:05 pmRNSSecond Price Monitoring Extn
25th Apr 20182:00 pmRNSPrice Monitoring Extension
25th Apr 20187:00 amRNSDistribution agreement with GE Healthcare
17th Apr 20187:00 amRNSHolding(s) in Company
16th Apr 20187:30 amRNSNew Company Structure and Directorate Change
16th Apr 20187:25 amRNSAppointment of non-executive director
9th Apr 20182:39 pmRNSHolding(s) in Company
29th Mar 20187:00 amRNSEquity Fundraising to raise £440,000
21st Mar 20189:01 amRNSHolding(s) in Company
16th Mar 20185:11 pmRNSHolding(s) in Company
16th Mar 20187:00 amRNSDirectorate Change
8th Mar 20188:48 amRNSHolding(s) in Company
7th Mar 20182:39 pmRNSHolding(s) in Company
1st Mar 20181:03 pmRNSHolding(s) in Company
26th Feb 20187:00 amRNSHalf-year Report
14th Feb 20187:00 amRNSDirectorate Change
9th Feb 201812:04 pmRNSHolding(s) in Company
5th Feb 20181:56 pmRNSHolding(s) in Company
28th Dec 20175:42 pmRNSHolding(s) in Company
28th Dec 20175:19 pmRNSTotal Voting Rights
20th Dec 20179:33 amRNSHolding(s) in Company
30th Nov 20174:38 pmRNSResult of AGM
22nd Nov 20179:37 amRNSHolding(s) in Company
22nd Nov 20177:00 amRNSPresentation at RSNA 2017
20th Nov 201712:40 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSFirst CE marked release of TexRAD® technology
7th Nov 20177:00 amRNSFinal Results
14th Sep 20177:00 amRNSHolding(s) in Company
31st Jul 20175:00 pmRNSTotal Voting Rights
28th Jul 201710:53 amRNSCCI Exclusive Distributor agreement with Boya
30th Jun 20172:21 pmRNSHolding(s) in Company
30th Jun 201712:41 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.